Physician profile
Kenny E Smith
NPI 1295736460
$1,368.05
in general payments reported to CMS, 2019-2025
20 companies · $52.64 in 2025
The $52.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $120 · 2021: $310 · 2022: $177 · 2023: $306 · 2024: $277 · 2025: $52.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $295.91 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $158.65 | 2023-2024 | Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $107.62 | 2021-2024 | |
| Lundbeck LLC | $104.87 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.77 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $74.94 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $71.27 | 2019 | |
| Neurelis, INC. | $66.98 | 2023 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $63.48 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $59.88 | 2023 | Gemtesa |
| Pfizer INC. | $51.56 | 2019-2024 | |
| Ucb, INC. | $48.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.20 | 2020 | |
| Axsome Therapeutics, INC. | $23.99 | 2023 | Sunosi |
| Neurocrine Biosciences, INC. | $23.21 | 2023 | Ingrezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $22.78 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.61 | 2024 | Caplyta |
| Lilly USA, LLC | $20.09 | 2021 | |
| Abbvie INC. | $17.87 | 2022 | |
| Acadia Pharmaceuticals INC | $15.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.